NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ADCT

Adc Therapeutics SA

May 23 • 04:00PM ET

2.43

Dollar change +0.20
Percentage change 8.97	%

Healthcare • Biotechnology • Switzerland • NYSE

Peers: GILD PFE AMGN LLY REGN VRTX JAZZ MRNA BMY INCY

| Held by: IWM IBB IWO IWN VTWO IWC RSSL IWV GSSC VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.45	Insider Own	21.45%	Shs Outstand	99.18M	Perf Week	28.57%
Market Cap	241.00M	Forward P/E	-	EPS next Y	-1.38	Insider Trans	0.83%	Shs Float	77.91M	Perf Month	78.68%
Income	-149.84M	PEG	-	EPS next Q	-0.40	Inst Own	53.61%	Short Float	5.74%	Perf Quarter	51.88%
Sales	75.82M	P/S	3.18	EPS this Y	1.44%	Inst Trans	2.78%	Short Ratio	11.04	Perf Half Y	17.96%
Book/sh	-2.40	P/B	-	EPS next Y	13.82%	ROA	-51.62%	Short Interest	4.47M	Perf Year	-34.85%
Cash/sh	1.96	P/C	1.24	EPS next 5Y	15.31%	ROE	-	52W Range	1.05 - 4.13	Perf YTD	22.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.38%	ROI	-71.25%	52W High	-41.16%	Beta	1.70
Dividend TTM	-	Quick Ratio	4.16	Sales past 5Y	70.77%	Gross Margin	88.48%	52W Low	131.43%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	4.46	EPS Y/Y TTM	47.31%	Oper. Margin	-165.54%	RSI (14)	70.86	Volatility	11.14% 10.37%
Employees	265	Debt/Eq	-	Sales Y/Y TTM	10.49%	Profit Margin	-197.64%	Recom	1.00	Target Price	8.20
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	36.22%	Payout	-	Rel Volume	2.32	Prev Close	2.23
Sales Surprise	30.06%	EPS Surprise	10.74%	Sales Q/Q	27.59%	Earnings	May 14 BMO	Avg Volume	404.68K	Price	2.43
SMA20	47.81%	SMA50	62.37%	SMA200	11.41%	Trades		Volume	937,532	Change	8.97%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-08-24	Initiated	Stephens	Overweight	$6
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

May-15-25 07:49AM	ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data (Clinical Trials Arena) -6.63%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-14-25 09:10AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +37.12%
08:00AM	ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update (PR Newswire)
07:45AM	ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) (PR Newswire)
09:42AM	Loading…
May-13-25 09:42AM	What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings (GuruFocus.com)
May-08-25 05:50PM	Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:15AM	ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 (PR Newswire)
May-01-25 05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 10:00AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +9.77%
07:00AM	ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Apr-01-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
07:15AM	ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
09:00PM	Loading…
Mar-31-25 09:00PM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.37%
Mar-27-25 11:17AM	ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript (SeekingAlpha)
08:35AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update (PR Newswire)
Mar-25-25 05:30PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 (PR Newswire)
Mar-24-25 11:08PM	ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 (SeekingAlpha)
Mar-20-25 07:15AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025 (PR Newswire) -6.59%
Feb-03-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -5.95%
Jan-30-25 07:15AM	ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (PR Newswire)
Jan-02-25 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
Dec-30-24 04:30PM	ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma (PR Newswire) -6.40%
Dec-11-24 07:30AM	ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (PR Newswire) -36.21%
Dec-09-24 07:30AM	ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma (PR Newswire)
Dec-06-24 07:30AM	ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial (PR Newswire) +63.02%
Dec-02-24 04:30PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire) -10.78%
02:02AM	Loading…
Nov-14-24 02:02AM	BerGenBio ASA (FRA:7BG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Leadership ... (GuruFocus.com) -6.03%
Nov-08-24 01:14PM	ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why (Benzinga)
Nov-07-24 08:50AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.44%
07:30AM	ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update (PR Newswire)
Nov-06-24 07:41AM	What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings (GuruFocus.com)
Nov-05-24 09:47AM	ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting (PR Newswire)
Nov-04-24 07:15AM	ADC Therapeutics to Present at November Investor Conferences (PR Newswire)
Nov-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (PR Newswire)
09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-31-24 07:15AM	ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire)
Oct-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
Sep-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -5.86%
07:15AM	ADC Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:40AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:30AM	ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) -7.83% -5.88%
Jul-30-24 07:15AM	ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024 (GlobeNewswire)
Jul-11-24 03:24PM	7 Growth Stocks to Buy for Under $5 for Massive Gains (InvestorPlace) +20.32%
Jul-08-24 02:00AM	Myricx Bio Announces 90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development (GlobeNewswire) -6.13%
Jul-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +16.46% -5.43%
Jun-27-24 07:15AM	ADC Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-13-24 02:31PM	Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget (InvestorPlace)
Jun-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +5.74%
May-30-24 07:15AM	ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 07:15AM	ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-09-24 07:01PM	Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT) (GuruFocus.com) -5.91%
07:15AM	ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 08:55AM	ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.54%
08:44AM	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating (MT Newswires)
May-06-24 10:53AM	ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -9.18%
08:22AM	ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell (MT Newswires)
07:30AM	ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
07:20AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:55AM	ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial (MT Newswires)
06:10AM	ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
06:00AM	ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma (GlobeNewswire)
May-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +6.80%
07:00AM	ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 (GlobeNewswire)
Apr-16-24 08:30AM	ADC Therapeutics Accelerates R&D with Genedata Biologics (PR Newswire)
Apr-04-24 07:00AM	ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +6.32%
Apr-03-24 07:00AM	ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 (GlobeNewswire)
Apr-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
Mar-15-24 12:30PM	ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 05:16AM	Q4 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:51AM	ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset (GuruFocus.com) -12.36%
08:20AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-24 07:15AM	ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit (GlobeNewswire)
07:00AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 (GlobeNewswire)
Mar-05-24 05:45PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-27-24 07:00AM	ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline (Zacks) -8.88%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey) +6.44%
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-19-24 01:05PM	ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why (Zacks)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-04-24 10:05AM	ADC Therapeutics, Aldeyra start off New Year with program discontinuations (FierceBiotech.com) +13.25%
07:15AM	ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Provides Business Updates (GlobeNewswire)
Dec-12-23 05:15AM	ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (GlobeNewswire)
Nov-20-23 02:40AM	Sobi to present new data at ASH 2023 Annual Meeting (PR Newswire)
Nov-15-23 03:00AM	Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors (GlobeNewswire) +6.15%
Nov-08-23 01:26PM	ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript (Insider Monkey) -17.26%
01:03AM	Q3 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:15AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -15.97%
07:15AM	ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-23 07:00AM	ADC Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +7.87%
Nov-02-23 05:50PM	Puma Biotech (PBYI) Tops Q3 Earnings Estimates (Zacks) +14.27%

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Redmile Group, LLC	10% Owner	Dec 11 '24	Buy	3.04	100,000	304,500	15,666,731	Dec 13 09:00 PM
Redmile Group, LLC	10% Owner	Dec 11 '24	Buy	3.04	100,000	304,500	13,145,712	Dec 13 09:00 PM
Redmile Group, LLC	10% Owner	Dec 04 '24	Sale	2.07	25,352	52,479	15,566,731	Dec 06 09:00 PM
Redmile Group, LLC	10% Owner	Jul 01 '24	Buy	2.81	400,000	1,124,000	15,669,217	Jul 03 08:00 PM
Redmile Group, LLC	10% Owner	Jul 01 '24	Buy	2.81	400,000	1,124,000	12,995,040	Jul 03 08:00 PM
Azelby Robert	Director	Jun 17 '24	Sale	2.89	6,995	20,216	53,005	Jun 18 09:45 PM
BIZZARI JEAN-PIERRE	Director	Jun 17 '24	Sale	2.89	6,995	20,216	79,502	Jun 18 09:43 PM
Hug Peter	Director	Jun 17 '24	Sale	2.89	1,193	3,448	182,644	Jun 18 09:41 PM
Monges Viviane	Director	Jun 17 '24	Sale	2.89	1,437	4,153	106,627	Jun 18 09:40 PM
Pfisterer Thomas	Director	Jun 17 '24	Sale	2.89	1,437	4,153	213,900	Jun 18 09:38 PM
Sandor Victor	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,886	Jun 18 09:37 PM
Squarer Ron	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,663	Jun 18 09:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADCT

Adc Therapeutics SA

Upgrade your FINVIZ experience